Technology and Type 1 Diabetes: Closed-Loop Therapies

  title={Technology and Type 1 Diabetes: Closed-Loop Therapies},
  author={T. Ly and B. Buckingham},
  journal={Current Pediatrics Reports},
AbstractThe concept of a closed-loop, automated insulin delivery system, with continuous glucose sensing and insulin delivery informed by a control algorithm without patient intervention, offers the potential to decrease the burden of diabetes management and modify the significant glycemic excursions associated with conventional therapy. Closed-loop technology represents a change in the treatment paradigm for diabetes as the transition is made from primarily self-management behaviors to… Expand
The Artificial Pancreas
It’s been nearly a century since the discovery of insulin and its role in managing blood glucose in patients with diabetes and despite the commercial availability of insulin pumps, continuous glucose monitoring, and rapid-acting insulin, patients with type 1 diabetes continue to struggle to meet glycemic targets. Expand
Using Cluster Analysis to Understand Clinician Readiness to Promote Continuous Glucose Monitoring Adoption
Clinician “personas” are developed with regard to readiness to promote CGM uptake to help facilitate increased uptake of CGM technology. Expand
Trust in hybrid closed loop among people with diabetes: Perspectives of experienced system users
This qualitative study explored trust in 32 individuals following a hybrid closed loop trial and found systems may be able to engage users by offering varying levels of controls to match trust preferences. Expand


The Use of an Automated, Portable Glucose Control System for Overnight Glucose Control in Adolescents and Young Adults With Type 1 Diabetes
These results suggest that the PGCS, an automated closed-loop device, is safe and effective in achieving overnight glucose control in patients with type 1 diabetes. Expand
Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.
Unsupervised overnight closed-loop insulin delivery at home is feasible and could improve glucose control in adults with type 1 diabetes. Expand
Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial Pancreas
CLC running on a smartphone (DiAs) in outpatient conditions reduced hypoglycemia and hypoglyCEmia treatments when compared with sensor-augmented pump therapy. Expand
Analysis of Glucose Responses to Automated Insulin Suspension With Sensor-Augmented Pump Therapy
Blood glucose profiles following a full 2-h insulin suspension activated by the LGS function suggest that this technology is safe and unlikely to be associated with adverse outcomes. Expand
Overnight Glucose Control With an Automated, Unified Safety System in Children and Adolescents With Type 1 Diabetes at Diabetes Camp
The DIAS USS algorithm is effective in improving time spent in range as well as reducing nocturnal hypoglycemia during the overnight period in children and adolescents with type 1 diabetes in a diabetes camp setting. Expand
Overnight Closed-Loop Insulin Delivery in Young People With Type 1 Diabetes: A Free-Living, Randomized Clinical Trial
Unsupervised home use of overnight closed loop in adolescents with type 1 diabetes is safe and feasible and glucose control was improved during the day and night with fewer episodes of nocturnal hypoglycemia. Expand
Fully Integrated Artificial Pancreas in Type 1 Diabetes
Integrated closed-loop control (CLC), combining continuous glucose monitoring (CGM) with insulin pump (continuous subcutaneous insulin infusion [CSII]), known as artificial pancreas, can helpExpand
Effect of sensor-augmented insulin pump therapy and automated insulin suspension vs standard insulin pump therapy on hypoglycemia in patients with type 1 diabetes: a randomized clinical trial.
Sensor-augmented insulin pump with automated low-glucose insulin suspension reduced the combined rate of severe and moderate hypoglycemia in patients with type 1 diabetes. Expand
Prevention of Nocturnal Hypoglycemia Using Predictive Alarm Algorithms and Insulin Pump Suspension
Using algorithms to shut off the insulin pump when hypoglycemia is predicted, it is possible to prevent hypoglyCEmia on 75% of nights (84% of events) when it would otherwise be predicted to occur. Expand
Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies
It is suggested that closed loop delivery of insulin may improve overnight control of glucose levels and reduce the risk of nocturnal hypoglycaemia in adults with type 1 diabetes. Expand